Comparison of MIBG Uptake in the Major Salivary Glands Between Lewy Body Disease and Progressive Supranuclear Palsy

Overview

Journal Clin Park Relat Disord

Date 2024 Dec 11

PMID 39659394

Authors

Junya Ebina

Sunao Mizumura

Mari Shibukawa

Harumi Morioka

Junpei Nagasawa

Masaru Yanagihashi

Takehisa Hirayama

Nobutomo Ishii

Yukio Kobayashi

Akira Inaba

Satoshi Orimo

Osamu Kano

Affiliations

Soon will be listed here.

Abstract

Introduction: Cardiac sympathetic denervation is specific to Lewy body disease (LBD). In Parkinson's disease (PD), sympathetic denervation in the major salivary glands (parotid glands [PG] and submandibular glands [SMG]) has been demonstrated by I-metaiodobenzylguanidine (MIBG) scintigraphy. We compared sympathetic denervation in the MSG between PD, dementia with Lewy bodies (DLB), and progressive supranuclear palsy (PSP).

Methods: We recruited 81 patients with PD, 12 with DLB, 13 with PSP and 25 with control subjects. We evaluated MIBG uptake in the major salivary glands and heart using a quantitative semi-automatic method. We compared MIBG uptake between PD, DLB, and PSP patients and controls, and we evaluated disease sensitivity and specificity. We compared olfactory function with MIBG uptake between PD and PSP patients.

Results: MIBG uptake in the PG and SMG in the delayed phase was significantly lower in PD and DLB patients than in PSP patients and controls. Conversely, MIBG uptake in the major salivary glands and heart was comparable between PD and DLB. Between LBD and non-LBD, MIBG uptake showed 56-100 % specificity in the PG, while it had 55.6-87.5 % sensitivity in the SMG. Between PD and PSP, MIBG uptake in the PG and SMG had higher disease specificity than olfactory function, while the sensitivity of SMG MIBG uptake was comparable to olfactory function.

Conclusion: PD and DLB patients showed lower MIBG uptake in the major salivary glands than PSP patients, especially in the delayed phase. MIBG uptake in the major salivary glands may differentiate PD from hyposmic PSP.

References

Yoshita M . Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J Neurol Sci. 1998; 155(1):60-7. DOI: 10.1016/s0022-510x(97)00278-5. View

Takahashi M, Ikemura M, Oka T, Uchihara T, Wakabayashi K, Kakita A . Quantitative correlation between cardiac MIBG uptake and remaining axons in the cardiac sympathetic nerve in Lewy body disease. J Neurol Neurosurg Psychiatry. 2015; 86(9):939-44. DOI: 10.1136/jnnp-2015-310686. View

Schubert E, Dogan S, Dillmann U, Schaefer-Schuler A, Fassbender K, Ezziddin S . MIBG scintigraphy of the major salivary glands in progressive supranuclear palsy and corticobasal degeneration. Parkinsonism Relat Disord. 2019; 66:247-248. DOI: 10.1016/j.parkreldis.2019.07.003. View

Marsili L, Rizzo G, Colosimo C . Diagnostic Criteria for Parkinson's Disease: From James Parkinson to the Concept of Prodromal Disease. Front Neurol. 2018; 9:156. PMC: 5877503. DOI: 10.3389/fneur.2018.00156. View

Haqparwar J, Pepe A, Fassbender K, Dillmann U, Ezziddin S, Schaefer A . Reduced MIBG accumulation of the parotid and submandibular glands in idiopathic Parkinson's disease. Parkinsonism Relat Disord. 2016; 34:26-30. DOI: 10.1016/j.parkreldis.2016.10.011. View

Orimo S, Suzuki M, Inaba A, Mizusawa H . 123I-MIBG myocardial scintigraphy for differentiating Parkinson's disease from other neurodegenerative parkinsonism: a systematic review and meta-analysis. Parkinsonism Relat Disord. 2012; 18(5):494-500. DOI: 10.1016/j.parkreldis.2012.01.009. View

Soboll L, Leppert D, Dillmann U, Schaefer-Schuler A, Fassbender K, Ezziddin S . MIBG scintigraphy of the major salivary glands in multiple system atrophy. Parkinsonism Relat Disord. 2018; 53:112-114. DOI: 10.1016/j.parkreldis.2018.04.034. View

McKeith I, Boeve B, Dickson D, Halliday G, Taylor J, Weintraub D . Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017; 89(1):88-100. PMC: 5496518. DOI: 10.1212/WNL.0000000000004058. View

Hoglinger G, Respondek G, Stamelou M, Kurz C, Josephs K, Lang A . Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov Disord. 2017; 32(6):853-864. PMC: 5516529. DOI: 10.1002/mds.26987. View

10.

Horsager J, Andersen K, Knudsen K, Skjaerbaek C, Fedorova T, Okkels N . Brain-first versus body-first Parkinson's disease: a multimodal imaging case-control study. Brain. 2020; 143(10):3077-3088. DOI: 10.1093/brain/awaa238. View

11.

Lamotte G, Holmes C, Sullivan P, Lenka A, Goldstein D . Cardioselective peripheral noradrenergic deficiency in Lewy body synucleinopathies. Ann Clin Transl Neurol. 2020; 7(12):2450-2460. PMC: 7732242. DOI: 10.1002/acn3.51243. View

12.

Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin R . Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996; 47(1):1-9. DOI: 10.1212/wnl.47.1.1. View

13.

Ebina J, Mizumura S, Morioka H, Shibukawa M, Nagasawa J, Yanagihashi M . Clinical characteristics of patients with Parkinson's disease with reduced I-metaiodobenzylguanidine uptake in the major salivary glands and heart. J Neurol Sci. 2024; 458:122932. DOI: 10.1016/j.jns.2024.122932. View

14.

Roemer S, Brendel M, Gnorich J, Malpetti M, Zaganjori M, Quattrone A . Subcortical tau is linked to hypoperfusion in connected cortical regions in 4-repeat tauopathies. Brain. 2024; 147(7):2428-2439. DOI: 10.1093/brain/awae174. View

15.

Tateno F, Sakakibara R, Kishi M, Ogawa E, Terada H, Ogata T . Sensitivity and specificity of metaiodobenzylguanidine (MIBG) myocardial accumulation in the diagnosis of Lewy body diseases in a movement disorder clinic. Parkinsonism Relat Disord. 2011; 17(5):395-7. DOI: 10.1016/j.parkreldis.2011.02.001. View

16.

Adler C, Dugger B, Hentz J, Hinni M, Lott D, Driver-Dunckley E . Peripheral Synucleinopathy in Early Parkinson's Disease: Submandibular Gland Needle Biopsy Findings. Mov Disord. 2016; 31(2):250-6. PMC: 4747813. DOI: 10.1002/mds.26476. View

17.

Jacobson A, Travin M . Impact of medications on mIBG uptake, with specific attention to the heart: Comprehensive review of the literature. J Nucl Cardiol. 2015; 22(5):980-93. DOI: 10.1007/s12350-015-0170-z. View

18.

Postuma R, Berg D, Stern M, Poewe W, Olanow C, Oertel W . MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015; 30(12):1591-601. DOI: 10.1002/mds.26424. View

19.

Nagayama H, Hamamoto M, Ueda M, Nagashima J, Katayama Y . Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson's disease. J Neurol Neurosurg Psychiatry. 2005; 76(2):249-51. PMC: 1739515. DOI: 10.1136/jnnp.2004.037028. View

20.

Nakajima K, Okuda K, Matsuo S, Yoshita M, Taki J, Yamada M . Standardization of metaiodobenzylguanidine heart to mediastinum ratio using a calibration phantom: effects of correction on normal databases and a multicentre study. Eur J Nucl Med Mol Imaging. 2011; 39(1):113-9. DOI: 10.1007/s00259-011-1963-1. View